{"url_path":"/sec/dcoy/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-214816-index.html","accession_number":"0001193125-26-214816","cik":"0001615219","ticker":"DCOY","issuer_name":"Decoy Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-214816-index.html","primary_entity_key":"0001615219","primary_entity_name":"Decoy Therapeutics Inc."},"word_count":48,"has_tables":true,"body_markdown":"Item 5. Other Information\n\nDuring the fiscal quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408 of Regulation S-K).\n\n25\n\n[Table of Contents](#toc_page)"}